GLYCOPEPTIDE ANTIBIOTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Glycopeptide Antibiotics Market, by Drug (Vancocin, Orbactiv, Dalvance, Kimyrsa, and Others), by Disease Indication (Clostridium difficile-associated Diarrhea, Endocarditis, Skin Structure Infections, and Others), by Distribution channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032

Published In: 29 Apr, 2026
Code: CMI5455
Page number: 154
Formats: Excel and PDF
Industry: Pharmaceutical
- Historical Range : 2020 - 2024
- Base Year : 2025
- Estimated Year : 2026
- Forecast Period : 2026-2033

Table of Contents (Version-2026)

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snippet, By Drug
  - Market Snippet, By Disease Indication
  - Market Snippet, By Distribution Channel
  - Market Snippet, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Key Development Strategies
- Mergers And Acquisition Scenario
- Market Trends
- Brand Analysis
- Regulatory Scenario
- PEST Analysis
- Pricing Analysis
Global Glycopeptide Antibiotics Market, By Drug, 2021 – 2033, (US$ Mn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022–2033
  - Segment Trends
- Vancocin
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
- Orbactiv
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
- Dalvance
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
- Kimyrsa
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
Global Glycopeptide Antibiotics Market, By Disease Indication, 2021 – 2033, (US$ Mn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022–2033
  - Segment Trends
- Clostridium difficile-associated Diarrhea
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
- Endocarditis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
- Skin Structure Infections
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
Global Glycopeptide Antibiotics Market, By Distribution Channel, 2021 – 2033, (US$ Mn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022–2033
  - Segment Trends
- Hospital Pharmacy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
- Retail Pharmacy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
- Online Pharmacy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
Global Glycopeptide Antibiotics Market, By Region, 2021 – 2033, (US$ Mn)
- Introduction
  - Market Share Analysis, By Region, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, For Regions, 2022–2033
- North America
  - Market Size and Forecast, By Drug, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Disease Indication, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Distribution Channel, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Country, 2021 – 2033, (US$ Mn)
    - U.S.
    - Canada
- Latin America
  - Market Size and Forecast, By Drug, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Disease Indication, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Distribution Channel, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Country, 2021 – 2033, (US$ Mn)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - Market Size and Forecast, By Drug, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Disease Indication, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Distribution Channel, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Country, 2021 – 2033, (US$ Mn)
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Market Size and Forecast, By Drug, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Disease Indication, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Distribution Channel, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Country, 2021 – 2033, (US$ Mn)
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - Market Size and Forecast, By Drug, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Disease Indication, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Distribution Channel, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Country, 2021 – 2033, (US$ Mn)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Market Size and Forecast, By Drug, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Disease Indication, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Distribution Channel, 2021 – 2033, (US$ Mn)
  - Market Size and Forecast, By Region/Country, 2021 – 2033, (US$ Mn)
    - South Africa
    - Central Africa
    - North Africa
Competitive Landscape
- Competitive Snapshot
  - ANI Pharmaceuticals, Inc.
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Fresenius SE & Co. KGaA
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Pfizer Inc
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Mylan N.V.
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Novartis AG
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Hikma Pharmaceuticals plc
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Aurobindo Pharma
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- AbbVie Inc.
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Melinta Therapeutics, Inc
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Cumberland Pharmaceuticals Inc
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Theravance Biopharma
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Janssen Global Services, LLC
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Bristol-Myers Squibb Company
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- GlaxoSmithKline plc.
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
Section
- References
- Research Methodology
- About us and Sales Contact

*Browse 22 market data tables and 18 figures on "Global Glycopeptide Antibiotics Market” - forecast to 2033

Get Instant Access - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now